Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193,394,759
-
Total 13F shares
-
31,012,787
-
Share change
-
+175,326
-
Total reported value
-
$100,791,065
-
Put/Call ratio
-
2375%
-
Price per share
-
$3.25
-
Number of holders
-
46
-
Value change
-
+$962,388
-
Number of buys
-
19
-
Number of sells
-
28
Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q1 2017
As of 31 Mar 2017,
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,012,787 shares.
The largest 10 holders included
QVT Financial LP, PRIMECAP MANAGEMENT CO/CA/, D. E. Shaw & Co., Inc., ARMISTICE CAPITAL, LLC, RTW INVESTMENTS, LP, Falcon Edge Capital LP, BANK OF MONTREAL /CAN/, AXA, SABBY MANAGEMENT, LLC, and K2 PRINCIPAL FUND, L.P..
This page lists
47
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.